RxDoctor Payments Data

Jeffrey Moore, MD

Internal Medicine · Stephenville, TXNPI 1023014008

Payments from drug & device makers

$3,224in general payments, 2019–2025

Across 177 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$229
  • Amgen$222
  • Boehringer Ingelheim$201
  • Novo Nordisk$162
  • Alphatec Spine, Inc$150
  • Exact Sciences$134
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$3,224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,224 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$295,611
Medicare patients
385
Services billed
7,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$148,289
OzempicSemaglutide71$70,477
MyrbetriqMirabegron48$29,834
JardianceEmpagliflozin28$29,646
JanuviaSitagliptin Phosphate32$27,880
Tresiba Flextouch U-100Insulin Degludec42$25,499
XareltoRivaroxaban27$24,556
CreonLipase/Protease/Amylase19$22,069
MounjaroTirzepatide15$15,926
LinzessLinaclotide17$14,860
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen502$13,430
Breo ElliptaFluticasone/Vilanterol21$12,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,917
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$10,530
Gabapentin530$7,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$107$156,769301 claims
Novo NordiskOzempic$162$70,47771 claims
AbbVieCreon, Linzess$83$36,92936 claims
MerckJanuvia, Janumet$127$34,98457 claims
Astellas Pharma US IncMyrbetriq$123$29,83448 claims
Boehringer IngelheimJardiance$201$29,64628 claims
Johnson & JohnsonXarelto$229$24,55627 claims
GSKBreo Ellipta, Trelegy Ellipta$96$23,21732 claims
Lilly USA, LLCMounjaro$87$15,92615 claims
AstraZenecaSymbicort$128$7,69826 claims
Sanofi-aventis U.S. LLCLantus$51$3,03037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Stephenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →